PDCD1 and gastric cancer: On the basis of phase II and phase III trials, the PD-1 (programmed death 1) inhibitors nivolumab and pembrolizumab were already approved in mono- and in combination therapy of advanced GC in first- or third-line settings in Europe, the USA and Taiwan (see Table 1).